Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes

Paolo Fiorina, Mollie Jurewicz, Andrea Augello, Andrea Vergani, Shirine Dada, Stefano La Rosa, Martin Selig, Jonathan Godwin, Kenneth Law, Claudia Placidi, R. Neal Smith, Carlo Capella, Scott Rodig, Chaker N. Adra, Mark Atkinson, Mohamed H. Sayegh, Reza Abdi

Research output: Contribution to journalArticle

273 Citations (Scopus)

Abstract

Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem cells (MSC) are presently underway without prior validation in a mouse model for the disease. In response to this void, we characterized bone marrow-derived murine MSC for their ability to modulate immune responses in the context of T1D, as represented in NOD mice. In comparison to NOD mice, BALB/c-MSC mice were found to express higher levels of the negative costimulatory molecule PD-L1 and to promote a shift toward Th2-like responses in treated NOD mice. In addition, transfer of MSC from resistant strains (i.e., nonobese resistant mice or BALB/c), but not from NOD mice, delayed the onset of diabetes when administered to prediabetic NOD mice. The number of BALB/c-MSC trafficking to the pancreatic lymph nodes of NOD mice was higher than in NOD mice provided autologous NODMSC. Administration of BALB/c-MSC temporarily resulted in reversal of hyperglycemia in 90% of NOD mice (p = 0.002). Transfer of autologous NOD-MSC imparted no such therapeutic benefit. We also noted soft tissue and visceral tumors in NODMSC-treated mice, which were uniquely observed in this setting (i.e., no tumors were present with BALB/c- or nonobese resistant mice-MSC transfer). The importance of this observation remains to be explored in humans, as inbred mice such as NOD may be more susceptible to tumor formation. These data provide important preclinical data supporting the basis for further development of allogeneic MSC-based therapies for T1D and, potentially, for other autoimmune disorders.

Original languageEnglish
Pages (from-to)993-1004
Number of pages12
JournalJournal of Immunology
Volume183
Issue number2
DOIs
Publication statusPublished - Jul 15 2009

Fingerprint

Inbred NOD Mouse
Mesenchymal Stromal Cells
Type 1 Diabetes Mellitus
Bone Marrow
Neoplasms
Cell- and Tissue-Based Therapy
Hyperglycemia
Lymph Nodes
Clinical Trials

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Fiorina, P., Jurewicz, M., Augello, A., Vergani, A., Dada, S., La Rosa, S., ... Abdi, R. (2009). Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. Journal of Immunology, 183(2), 993-1004. https://doi.org/10.4049/jimmunol.0900803

Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. / Fiorina, Paolo; Jurewicz, Mollie; Augello, Andrea; Vergani, Andrea; Dada, Shirine; La Rosa, Stefano; Selig, Martin; Godwin, Jonathan; Law, Kenneth; Placidi, Claudia; Smith, R. Neal; Capella, Carlo; Rodig, Scott; Adra, Chaker N.; Atkinson, Mark; Sayegh, Mohamed H.; Abdi, Reza.

In: Journal of Immunology, Vol. 183, No. 2, 15.07.2009, p. 993-1004.

Research output: Contribution to journalArticle

Fiorina, P, Jurewicz, M, Augello, A, Vergani, A, Dada, S, La Rosa, S, Selig, M, Godwin, J, Law, K, Placidi, C, Smith, RN, Capella, C, Rodig, S, Adra, CN, Atkinson, M, Sayegh, MH & Abdi, R 2009, 'Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes', Journal of Immunology, vol. 183, no. 2, pp. 993-1004. https://doi.org/10.4049/jimmunol.0900803
Fiorina, Paolo ; Jurewicz, Mollie ; Augello, Andrea ; Vergani, Andrea ; Dada, Shirine ; La Rosa, Stefano ; Selig, Martin ; Godwin, Jonathan ; Law, Kenneth ; Placidi, Claudia ; Smith, R. Neal ; Capella, Carlo ; Rodig, Scott ; Adra, Chaker N. ; Atkinson, Mark ; Sayegh, Mohamed H. ; Abdi, Reza. / Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. In: Journal of Immunology. 2009 ; Vol. 183, No. 2. pp. 993-1004.
@article{a4e88253804a4b9f866bad16d9f99bfc,
title = "Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes",
abstract = "Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem cells (MSC) are presently underway without prior validation in a mouse model for the disease. In response to this void, we characterized bone marrow-derived murine MSC for their ability to modulate immune responses in the context of T1D, as represented in NOD mice. In comparison to NOD mice, BALB/c-MSC mice were found to express higher levels of the negative costimulatory molecule PD-L1 and to promote a shift toward Th2-like responses in treated NOD mice. In addition, transfer of MSC from resistant strains (i.e., nonobese resistant mice or BALB/c), but not from NOD mice, delayed the onset of diabetes when administered to prediabetic NOD mice. The number of BALB/c-MSC trafficking to the pancreatic lymph nodes of NOD mice was higher than in NOD mice provided autologous NODMSC. Administration of BALB/c-MSC temporarily resulted in reversal of hyperglycemia in 90{\%} of NOD mice (p = 0.002). Transfer of autologous NOD-MSC imparted no such therapeutic benefit. We also noted soft tissue and visceral tumors in NODMSC-treated mice, which were uniquely observed in this setting (i.e., no tumors were present with BALB/c- or nonobese resistant mice-MSC transfer). The importance of this observation remains to be explored in humans, as inbred mice such as NOD may be more susceptible to tumor formation. These data provide important preclinical data supporting the basis for further development of allogeneic MSC-based therapies for T1D and, potentially, for other autoimmune disorders.",
author = "Paolo Fiorina and Mollie Jurewicz and Andrea Augello and Andrea Vergani and Shirine Dada and {La Rosa}, Stefano and Martin Selig and Jonathan Godwin and Kenneth Law and Claudia Placidi and Smith, {R. Neal} and Carlo Capella and Scott Rodig and Adra, {Chaker N.} and Mark Atkinson and Sayegh, {Mohamed H.} and Reza Abdi",
year = "2009",
month = "7",
day = "15",
doi = "10.4049/jimmunol.0900803",
language = "English",
volume = "183",
pages = "993--1004",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes

AU - Fiorina, Paolo

AU - Jurewicz, Mollie

AU - Augello, Andrea

AU - Vergani, Andrea

AU - Dada, Shirine

AU - La Rosa, Stefano

AU - Selig, Martin

AU - Godwin, Jonathan

AU - Law, Kenneth

AU - Placidi, Claudia

AU - Smith, R. Neal

AU - Capella, Carlo

AU - Rodig, Scott

AU - Adra, Chaker N.

AU - Atkinson, Mark

AU - Sayegh, Mohamed H.

AU - Abdi, Reza

PY - 2009/7/15

Y1 - 2009/7/15

N2 - Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem cells (MSC) are presently underway without prior validation in a mouse model for the disease. In response to this void, we characterized bone marrow-derived murine MSC for their ability to modulate immune responses in the context of T1D, as represented in NOD mice. In comparison to NOD mice, BALB/c-MSC mice were found to express higher levels of the negative costimulatory molecule PD-L1 and to promote a shift toward Th2-like responses in treated NOD mice. In addition, transfer of MSC from resistant strains (i.e., nonobese resistant mice or BALB/c), but not from NOD mice, delayed the onset of diabetes when administered to prediabetic NOD mice. The number of BALB/c-MSC trafficking to the pancreatic lymph nodes of NOD mice was higher than in NOD mice provided autologous NODMSC. Administration of BALB/c-MSC temporarily resulted in reversal of hyperglycemia in 90% of NOD mice (p = 0.002). Transfer of autologous NOD-MSC imparted no such therapeutic benefit. We also noted soft tissue and visceral tumors in NODMSC-treated mice, which were uniquely observed in this setting (i.e., no tumors were present with BALB/c- or nonobese resistant mice-MSC transfer). The importance of this observation remains to be explored in humans, as inbred mice such as NOD may be more susceptible to tumor formation. These data provide important preclinical data supporting the basis for further development of allogeneic MSC-based therapies for T1D and, potentially, for other autoimmune disorders.

AB - Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem cells (MSC) are presently underway without prior validation in a mouse model for the disease. In response to this void, we characterized bone marrow-derived murine MSC for their ability to modulate immune responses in the context of T1D, as represented in NOD mice. In comparison to NOD mice, BALB/c-MSC mice were found to express higher levels of the negative costimulatory molecule PD-L1 and to promote a shift toward Th2-like responses in treated NOD mice. In addition, transfer of MSC from resistant strains (i.e., nonobese resistant mice or BALB/c), but not from NOD mice, delayed the onset of diabetes when administered to prediabetic NOD mice. The number of BALB/c-MSC trafficking to the pancreatic lymph nodes of NOD mice was higher than in NOD mice provided autologous NODMSC. Administration of BALB/c-MSC temporarily resulted in reversal of hyperglycemia in 90% of NOD mice (p = 0.002). Transfer of autologous NOD-MSC imparted no such therapeutic benefit. We also noted soft tissue and visceral tumors in NODMSC-treated mice, which were uniquely observed in this setting (i.e., no tumors were present with BALB/c- or nonobese resistant mice-MSC transfer). The importance of this observation remains to be explored in humans, as inbred mice such as NOD may be more susceptible to tumor formation. These data provide important preclinical data supporting the basis for further development of allogeneic MSC-based therapies for T1D and, potentially, for other autoimmune disorders.

UR - http://www.scopus.com/inward/record.url?scp=70249122431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249122431&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0900803

DO - 10.4049/jimmunol.0900803

M3 - Article

VL - 183

SP - 993

EP - 1004

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -